Warning issued on blood cancer drug

Idelalisib (Zydelig) should not be used in combination with rituximab in a range of patients with haematological malignancies, the TGA advises. The alert follows serious adverse events, including death, in patients receiving idelalisib and other cancer medicines as part of a phase 3 clinical trial which has since been discontinued. Patients with chronic lymphocytic leukaemia ...

Already a member?

Login to keep reading.

© 2021 the limbic